Please check your internet connection and try again.
# Montelukast-Levocetirizine (Combination Therapy)
## Overview
This combination pairs a selective leukotriene receptor antagonist (Montelukast) with a third-generation, non-sedating H1-receptor antagonist (Levocetirizine). While often prescribed concomitantly, they are distinct pharmacological agents.
## Primary Indications
* Allergic rhinitis (seasonal and perennial).
* Chronic urticaria.
* Asthma (Montelukast component).
## Adult Dosing
* **Montelukast:** 10 mg orally once daily, preferably in the evening.
* **Levocetirizine:** 5 mg orally once daily, preferably in the evening.
## Pediatric Dosing
* **6 months – 5 years:** Montelukast 4 mg (oral granules/chewable); Levocetirizine 1.25 mg (oral solution) daily.
* **6 – 11 years:** Montelukast 5 mg (chewable); Levocetirizine 2.5 mg (oral solution/tablet) daily.
* **12+ years:** Follow adult dosing.
## Dose Adjustments
* **Renal Impairment (Levocetirizine):** CrCl 50–80 mL/min: 2.5 mg daily; CrCl 30–49 mL/min: 2.5 mg every 48 hours; CrCl <30 mL/min: contraindicated.
* **Hepatic Impairment:** No specific adjustment for Montelukast. Levocetirizine should be used with caution in severe hepatic impairment.
## Contraindications
* **Hypersensitivity:** Known allergy to either component.
* **Severe Renal Impairment:** For Levocetirizine (CrCl <10 mL/min or hemodialysis).
## Adverse Effects
* **Montelukast:** Neuropsychiatric events (agitation, aggression, depression, sleep disturbances, suicidal ideation), headache, upper respiratory infection, abdominal pain.
* **Levocetirizine:** Somnolence, fatigue, nasopharyngitis, dry mouth.
## Key Drug Interactions
* **Montelukast:** Minimal; may be affected by potent CYP2C8, 2C9, and 3A4 inducers (e.g., rifampin).
* **Levocetirizine:** CNS depressants (alcohol, sedatives) may potentiate sedation. Ritonavir may increase levocetirizine exposure.
## Monitoring
* **Neuropsychiatric:** Monitor for mood changes, behavior, or sleep disturbances (Black Box Warning for Montelukast).
* **Renal:** Periodic CrCl assessment if using Levocetirizine in patients with declining renal function.
## Clinical Pearls
* **FDA Warning:** The FDA issued a boxed warning for Montelukast regarding serious neuropsychiatric events. Limit use to patients who cannot be treated with other therapies.
* **Timing:** Administer both medications in the evening; levocetirizine can cause mild sedation in some patients, and montelukast has proven efficacy in nocturnal asthma symptoms.
* **Evidence:** This combination is often studied in chronic urticaria refractory to H1-antihistamines alone, where the addition of a leukotriene antagonist may provide additive relief.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice protocols vary. Always verify current prescribing information, package inserts, and hospital-specific guidelines before prescribing or administering medication.
